12
Special Populations
Table 2. Vaccination of Persons With HIV Infection
Recommendation
Vaccine
Low-Level
a
or No
Immunosuppression
High-Level
Immunosuppression
b
H influenzae type b
conjugate
U: age <5 y (SR-H)
R: age 5–18 y
c
(SR-L)
U: age <5 y (SR-H)
R: age 5–18 y
c
(SR-L)
Hepatitis A U (SR-M) U: age 1 y (SR-M)
Hepatitis B
d
R (SR-M) R (SR-M)
DTaP U (SR-M) U (SR-M)
Tdap U (SR-VL) U (SR-VL)
Td U (SR-L) U (SR-L)
HPV4
e
U: age 11-26 y (SR-VL) U: age 11-26 y (SR-VL)
Influenza, inactivated U (SR-H) U (SR-H)
Influenza, live attenuated Xf (WR-VL) X (WR-VL)
MMR, live U: age 12 mo to 13 y
(SR-M)
U: age ≥14 y (WR-VL)
X: age 12 mo to 13 y (SR-M)
X: age ≥14 y (SR-M)
MMRV, live X (SR-VL) X (SR-VL)
Meningococcal conjugate
g
U: age 11-18 y (SR-M) U: age 11-18 y (SR-M)
Pneumococcal conjugate
(PCV13)
U: age <5 y (SR-M)
R: age 5 y
h
(SR-M)
R: age 6-18 y
h
(SR-L)
R: age ≥19 y
i
(SR-L)
U: age <5 y (SR-M)
R: age 5 y (SR-M)
R: age 6-18 y (SR-L)
R: age ≥19 y
i
(SR-VL)
Pneumococcal
polysaccharide (PPSV23)
j
R: age ≥2 y (SR-M) R: age 2-18 y (SR-M)
R: adult (CD4 T-lymphocytes
<200 cells/mm
3
) (WR-L)
Poliovirus, inactivated U (SR-M) U (SR-M)
Rotavirus, live U (SR-L) U (WR-VL)
Varicella, live U: age 1-8 y (SR-H)
U: age ≥9 y (SR-VL)
X (SR-M)
Zoster, live X: age <60 y (SR-L)
U: age ≥60 y (WR-L)
k, l
X (SR-M)
